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Abstract: Interventional studies are designed specifically to test the impact of a treatment or management
strategy on an outcome of interest. In this article, we will highlight two viewpoints regarding the role of
small or single-institution prospective interventional studies within the field of thoracic surgery: first, that
these studies are beneficial and can positively impact the field, and second, that these studies can have such
significant limitations that they may have no meaningful impact. We will also review elements that can make
for successful design and execution of small prospective interventional studies.
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Interventional studies are designed specifically to test
the impact of a treatment or management strategy on an
outcome of interest. These are frequently prospective
studies that compare a treated cohort with control patients,
and can take the form of randomized controlled trials,
pre- and post-implementation comparisons, or nonrandomized trials (1). These study designs are better
suited than retrospective observational studies to assess the
causative effect of an intervention, but still have limitations
and can be susceptible to different types of bias. Often,
considerable effort and resources are required to plan and
conduct an interventional study, and many factors can affect
the eventual impact of the results.
In this article, we will highlight two viewpoints
regarding the role of small or single-institution prospective
interventional studies within the field of thoracic surgery: first,
that these studies are beneficial and can positively impact the
field, and second, that these studies can have such significant
limitations that they may have no meaningful impact. A
summary of these viewpoints is included in Table 1. We will
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also review elements that can make for successful design and
execution of small prospective interventional studies.
Pro: these studies are beneficial and can
positively impact the field
Small or single-institutional prospective studies can be
employed for a variety of goals. These studies can be useful
for analyzing elements of daily clinical care, adding data to
dogmatic practice. They can also assess preliminary safety
and efficacy of new or innovative clinical practices, establish
feasibility of an intervention, or demonstrate proof of concept
that provides the basis for a larger study. They may also be
the ideal medium for collecting detailed subject patient data
or communicating relevant clinical experiential data to the
field. Several examples of such studies exist within thoracic
surgery, and demonstrate the utility of this type of research.
Thoracic surgeons regularly use historical dogma to
make daily clinical decisions, such as in the post-operative
management of chest tubes, but there is often a lack of data
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Table 1 A summary of highlighted benefits and limitations of small
prospective studies
Benefits
Can study individual elements of patient care
Can be quick and relatively inexpensive to conduct
Can assess preliminary safety of a new treatment
Can provide an estimate of efficacy of an intervention
Can establish proof of concept
Can establish feasibility of an intervention
Can collect detailed patient data beyond standard of care
more easily from a smaller cohort
Can be useful to communicate experiential knowledge to the
field
Can result in stepwise improvements to clinical care
Limitations
Can be subject to inadequate study design
Can be underpowered and subject to type II error
Can have false positive results, type I error, if rare events occur
in a small population
Can be affected by confounding, may not be able to
sufficiently adjust results due to sample size
Can have results that are not generalizable to other practice
settings
Can have excessively strict enrollment criteria and lead to a
test of efficacy rather than effectiveness
Can be susceptible to significant publication bias
Can be insufficient to change practice

that support these decisions. Prospective studies can help fill
the gap. Cerfolio and Bryant (2) produced a single-surgeon,
prospective study to challenge the often-cited “rule” that
it is unsafe to discontinue a chest tube with an output of
250 mL/day or more. By applying a prospective algorithm
of removing all chest tubes with less than 450 mL/day,
without an air leak and without chylothorax, they found that
over a 10-year period of over 8,600 pulmonary resections,
only 0.55% of patients were readmitted for symptomatic
pleural effusion. When compared to the overall group, the
cohort of patients that had chest tubes discontinued with
250–450 mL/day output had no significant difference
in readmission rate. Additionally, patients that were
discharged early on postoperative day 2 or 3 carried the
same readmission rate as the rest of the population. The
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significance of small, perspective studies in the management
of chest tubes is not confined to this study. Cerfolio et al. (3)
also utilized a prospective randomized trial to shed light on
whether water seal or suction is superior for resolving air
leaks after elective pulmonary resection. After developing
a system to quantify severity of air leaks, they followed
postoperative leaks over time in preoperatively-randomized
water seal and suction groups matched to control for risk
factors of leak. The randomization aspect of the trial was
halted after 67% of air leaks under water seal had resolved
by postoperative day 3 and only 7% of leaks under suction
had resolved by this time (P=0.001). They concluded
that water seal is superior to suction for resolving mild to
moderate air leaks according to their described severity
ranking, however, patients with large air leaks are at risk for
pneumothorax on water seal and should be placed to suction
to avoid this complication. These types of findings would be
difficult or impractical to study in a large randomized trial
and allow surgeons to utilize data-driven evidence when
making clinical patient care decisions. While the decision
of when to transition to water seal and when to pull a chest
tube may seem mundane, these types of daily considerations
have real implications on length of stay, treatment costs,
and the patient’s experience. Therefore, it is imperative that
these decisions are evidence-based. Small, single-institution
prospective studies can serve as a relatively quick, affordable,
and generalizable source of evidence to better inform
surgeons on daily clinical decisions that are often dictated by
dogma and anecdotal evidence.
Small-scale prospective studies also have the potential to
provide a relatively simple and timely means to evaluate the
safety and efficacy of new interventions that are either not
developed enough or not appropriate for more rigorous,
large-scale, randomized studies. One example is the use
of office spirometry for preoperative risk stratification
before lung resection instead of the traditionally used
formal laboratory-based spirometry. In a small-scale,
prospective, single-institution clinical trial, Hudson et al. (4)
created 52 clinical propensity matches between patients
assessed with office spirometry or laboratory spirometry.
Outcome analysis showed no statistical difference
between the matched office spirometry and laboratory
spirometry patients in terms of discharge from the hospital,
30-day mortality, postoperative respiratory failure, major
morbidity rate, and length of stay. The study also estimated
that appropriately using office spirometry rather than
laboratory spirometry would result in approximately
$38,000 in annual institutional cost savings. In summary,
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by appropriately implementing a single-institution, smallscale, prospective clinical trial, Hudson et al. were able to
effectively demonstrate the sufficiency, safety, and potential
cost savings of using only office spirometry for preoperative
pulmonary function screening before lung resection in
low-risk patients. Findings like this can have practicechanging implications in the field of thoracic surgery. At
a minimum, prospective trials can serve as the first form
of safety validation for newer diagnostic and treatment
patterns that are not yet widely accepted or are still being
scaled. The prospective study design is often able to show
the potential efficacy, safety, and cost-savings for new
clinical interventions by taking full advantage of singleinstitution data that may otherwise be underutilized.
A limiting factor in executing large-multicenter
trials is often cost. When a novel idea or intervention is
presented in the surgical arena, demonstrating proof of
concept can be valuable prior to organizing expensive
multicenter trials. Smaller-scale studies can provide
this preliminary assurance. Postoperative pneumonia
after elective pulmonary resection is a common and
life-threatening complication. In addition to affecting
morbidity and mortality, postoperative pneumonia can
greatly affect cost and length of stay. After recognizing
that oral hygiene regimens lower ventilator-associated
pneumonias, Washington University in St. Louis (5)
designed a single-arm interventional study to assess
the effect and feasibility of oral hygiene on pneumonia
rates after pulmonary resection. This study enrolled
62 patients into a pre- and postoperative chlorhexidine
toothbrushing intervention cohort and compared their
postoperative pneumonia rate (1.6%) to that of a timematched contemporaneous cohort (4.9%). While not
statistically significant (P=0.35), this small-scale study
showed an encouraging trend towards lower rates of
pneumonia that supports further larger-scale studies, and
provides a point estimate for appropriate statistical power
calculations. As important as effectiveness, this study
tested feasibility of the proposed oral hygiene regimen.
Preoperative adherence to the oral hygiene regimen was
high (87–100%). Postoperatively, 80% of patients opted to
continue participation, with median adherence of 86% in
this group. This revealed that patients were able to comply
with the inexpensive oral hygiene regimen proposed. In
summary, this study revealed that patients could adhere
to a perioperative oral hygiene regimen that may hold
promise for decreasing postoperative pneumonia rates.
Small-scale studies like this are an affordable and realistic
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way of assessing feasibility of a new intervention while
also gathering preliminary data before planning larger
appropriately-powered studies to better test effectiveness.
Prospective studies can also provide key insight into a
particular disease process that is otherwise difficult to study
through feasible means of subjective follow-up. An example
of this is Giant Paraesophageal Hernias (GPEH) that are
relatively rare and often misunderstood. Stringham et al. (6)
studied 106 GPEH patients at a single institution and found
that surgical repair is safe and carries a low postoperative
complication rate. Additionally, the study compared a
new, radiographic recurrence definition (any amount of
stomach above the diaphragm on barium swallow) to the
conventional recurrence definition most often used in
GPEH literature (>2 cm or >10% of the stomach above
the diaphragm) and found a 1-year radiographic recurrence
rate of 32.7% compared to a conventional recurrence rate
of 18.8%. Interestingly the patient satisfaction scores were
similar between the smaller and larger GPEH recurrences
(57.1% vs. 52.6%, respectively) but both were significantly
higher than the overall preoperative satisfaction score
average of 2.9%. Finally, this study used the validated
quality of life metric (GERD-HRQL), where high scores
suggest poor quality of life, to show that patients without
recurrence had significantly improved scores from 22.5 to
3.5 at 1 year from surgery, but that a recurrence of any kind
was associated with an increase in score to 13.0. Prospective
studies like this can help give thoracic surgeons a better
understanding of a disease and specifically the subjective
ramifications that it has on patient experience. This GPEH
study was able to show convincingly the significant impact
that a recurrence has on a patient postoperatively. It also
revealed a potential new paradigm in the diagnosis of
GPEH recurrence. This type of a prospective study was
able to take advantage of a relatively small sample size, with
a high follow-up rate (96.2% at 1 year) to gain outcome
data about a surgical disease. With quality of life and other
subjective indictors becoming more important in surgical
patient care and potentially even in medical billing, smallscale, feasible, prospective trials with high follow-up rates
could provide thoracic surgeons much needed insight into
the patient experience.
When a new treatment or intervention is introduced,
multiple centers often discover similar shortcomings before
independently adjusting and adapting. Small prospective
studies on new practices can provide helpful insight into
recognized trends, problems encountered, and knowledge
gained that may be useful to many institutions. One example
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is enhanced recovery after surgery (ERAS) pathways. There
is a growing trend toward standardized ERAS protocols as
data shows improved outcome measures with standardized
and intentional postoperative care. These pathways can
vary greatly between institutions. Martin et al. (7) at the
University of Virginia introduced two thoracic ERAS
protocols, one for VATS (n=81) and one for thoracotomy
(n=58), and compared outcomes data to historic controls
after 1 year. Both protocols showed significant decreases
in postoperative opioids, total fluid balance, and hospital
cost. ERAS after thoracotomy also showed a significant
decrease in length of stay. While their preliminary data
on the improvement of outcome measures is valuable,
their detailed narrative of interventions made, problems
encountered, and corresponding adjustments made to
the pathway over the course of a year is widely useful to
institutions developing similar protocols. By sharing this
insight into the development of new interventions such as
ERAS protocols, small prospective studies can encourage an
efficient and collaborative approach across many institutions
with the shared goal of improving patient experience.
Stepwise improvements in patient care can result
from studies like these. Appropriate design, analysis,
and presentation of small-scale studies are critical for
maximizing the impact of the findings, but the attributes
highlighted here demonstrate the utility that a small or
single-institution study can have within the field.
Con: these studies can have such significant
limitations that they may have no meaningful
impact
Small studies can be subject to inadequate statistical study
design, methodological pitfalls, or other shortcomings that
can severely limit their impact, or may preclude publication
altogether. Potential limitations in study planning, conduct,
analysis, and publication merit consideration.
One major risk with small or single-institution studies
is that they may be underpowered and subject to type
II error, meaning that even if there is a real effect of
the intervention, the analysis may not show a statistical
difference. One example of this is demonstrated by a small
preliminary prospective randomized trial by Geddes et al. (8)
that examined the effect of lung volume reduction surgery
(LVRS) versus medical management for patients with
severe emphysema. They randomized a total of 48 patients
and found that, while there were statistically significant
improvements in pulmonary function studies, walking
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distance, and quality of life, there was not an observed
benefit in mortality with one strategy versus the other. In
the subsequent National Emphysema Treatment Trial (9),
which randomized a total of 1,218 patients to LVRS or
medical treatment, there was sufficient statistical power
to perform subgroup analyses based on the distribution of
emphysema and baseline exercise capacity. This trial showed
that for certain subgroups of patients with high baseline
exercise capacity, there actually were significant differences
in mortality: in predominantly upper-lobe disease, LVRS
actually was associated with a lower risk of mortality,
whereas for patients with non-upper lobe emphysema,
LVRS carried a higher risk of mortality. These disparate
findings are very important to patient selection, but were
not apparent in smaller studies. The statistical power, or the
ability to detect a difference in outcomes between groups if
it exists, is predominantly dependent on sample size and the
effect size of the intervention. Within a small-scale study,
interventions that have a large effect may yield statistically
significant results, while those that have a smaller, yet real,
effect may not. While data on estimated effect size can
be used to determine the necessary sample size to avoid
a futile underpowered study, this is not always done for
a variety of reasons, ranging from lack of availability of
the necessary data in the context of preliminary studies to
simply poor trial planning. Even if a goal sample size is
estimated properly, it may not prove feasible to enroll the
target number of patients in a single-institution study. It
is therefore necessary to interpret negative results of small
studies with trial design and statistical power in mind.
Another concern is the risk of false positive results, or a
type I error. Rare events may have an unwarranted effect
on a study’s conclusions if they occur in a small population,
and this can pose a significant threat to the validity of a
study. A notable example of such questionable findings is
an analysis of stereotactic body radiation therapy (SBRT)
versus lobectomy for stage I lung cancer (10), which pooled
a total of 58 patients from two randomized trials (STARS
and ROSEL) that were closed early due to poor enrollment.
Of the 27 patients in the surgery group, 6 died, reflecting a
much higher than expected mortality rate from lobectomy.
Only one of the 31 patients receiving SBRT died, which
resulted in their analysis showing a statistically significant
difference in survival. A statistical study by Samson et al. (11)
examined the stability of the survival estimates from
small versus large cohorts of patients by performing a
bootstrapping analysis of an institutional sample of stage
I lung cancer patients who would have met criteria for
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inclusion in one of the randomized trials. They found that
with a cohort of 27 patients (the actual number included in
the pooled analysis), expected survival estimates at 3-year
varied widely from 46–100%, whereas with a cohort of 515
(the planned surgical enrollment of one of the randomized
trials), the estimates ranged only from 70–85%. This is the
reason that many clinical trials have planned preliminary
analyses that take a very conservative early approach to
avoid prematurely declaring superiority of a treatment
based on chance events in a small sample size (12). Small
studies that demonstrate much higher than expected event
rates in one or both treatment arms should be interpreted
with caution.
Additionally, confounding can be an issue in these
studies. Randomization should theoretically distribute
risk factors between intervention and control groups, but
for practical reasons, many of these prospective studies
are not randomized. As a result, an apparent effect of the
intervention may in fact be due to one or more unequally
distributed risk factors for the outcome of interest between
the groups: confounding. A common approach to adjusting
for potential confounding variables is performance of a
multivariable analysis. A valid and reliable multivariable
analysis including all relevant covariates may not be able
to be performed with too few outcomes. A general rule is
that ten outcomes are required for each variable included
in the model (13), meaning that a small sample size in a
study with few outcomes can preclude performance of
a statistically sound multivariable analysis. Even when
performed properly with sufficient outcomes, multivariable
analysis only removes confounding from variables that were
measured and included in the model, again emphasizing
the importance of a properly designed study. Furthermore,
some prospective studies are performed with a single
interventional arm only, and initially encouraging results
may not be confirmed when an intervention is tested in a
trial, where additional important prognostic variables are
taken into account. For example, Voynov et al. (14) reported
outcomes from a series of 110 patients with stage I lung
cancer who, because of poor lung function, underwent
sublobar resection with placement of a brachytherapy mesh
along the surgical margin and surrounding visceral pleura.
They found an encouraging local control rate of 90% at
5 years, prompting enthusiasm for use of brachytherapy.
The subsequent ACOSOG Z4032 trial was performed (15)
and 224 high-risk patients undergoing sublobar resection
were randomized to receipt of brachytherapy versus surgery
alone. This trial demonstrated that there was no difference
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in rates of local control (HR 1.01, P=0.98) or 3-year
survival (71% for both groups, P=0.97). This demonstrates
the importance of an appropriate comparison group and
consideration of relevant covariates.
Another limitation is that results from small studies
conducted in a single institution may not be reproducible
or generalizable elsewhere. Idiosyncratic circumstances may
exist at small centers that contribute to study outcomes.
Additionally, if rigorous inclusion and exclusion criteria
are implemented that significantly limit the population, a
study may be assessing the efficacy of the intervention—
that is, how well it works in an ideal setting—rather than
the effectiveness of the intervention—or how well it might
be expected to work under more commonplace real-world
circumstances (16). Often in studies, the patients most likely
to benefit from an intervention are selected for participation
through strict enrollment criteria. This frequently
contributes to the ‘success’ of a study in demonstrating
a statistically significant benefit of an intervention, but
leaves providers questioning the expected benefit to their
general patient population. The results may not be able
to be extrapolated, or, while the intervention may still
have an effect, it may be much smaller in magnitude than
that demonstrated in the study. Attention to the patient
population and study design can help a provider interpret
how pragmatic the findings of a study are, and consideration
of appropriate patient selection in trial planning can help
maximize the applicability of the results.
Finally, significant publication bias affects this type of
study, even for properly executed trials: many of the studies
that do not show a statistically significant difference may
never be published. Many reasons for the lower rate of
publication of negative studies are often cited, though the
most common explanation is that they are never submitted
for consideration. Often this is due to perceived lack of
interest in the results, an assumption that a journal will not
be willing to publish the study, or that there is no personal
or patient benefit to publication of negative results (17).
This bias in publication not only limits the available primary
literature, but also can inappropriately impact the findings
of systematic reviews and meta-analyses, leading essentially
to inaccuracies in what is frequently considered the highest
level of evidence (17).
Because of these potential shortcomings, small studies
can sometimes be considered futile efforts. Alone, they may
not provide sufficient credible evidence to modify practice
within the field, or even for individual practitioners. The
limitations reviewed here demonstrate why clinical practice
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may not change in response to small or single-institution
study findings.
Summary and recommendations
Consideration of certain elements can make for successful
design and execution of small prospective studies. First,
one should be mindful of several qualities in the conception
and development of the project proposal. An appropriately
focused clinical question must be selected. The effect of
a single intervention should be investigated in a clearly
defined patient population with specified inclusion and
exclusion criteria. The trial itself needs to be properly
designed, with an appropriate comparison or control group
selected that is subject to the same predefined criteria.
Randomization of patients to intervention or control groups
is the gold-standard approach to minimize confounding, but
time-matched, propensity-matched, or historical controls
may be reasonable in certain circumstances. Thought
should also be given to sample size. If preliminary data is
available, power calculations should be performed to dictate
target enrollment. For novel interventions, small pilot
studies may be useful to assess feasibility of the intervention
and to obtain a point estimate of effect size to perform power
calculations for a planned larger trial. Furthermore, smallscale studies are appropriate when testing an intervention that
deviates from existing standard of care and may carry safety
concerns. Interval analysis and monitoring should be planned.
Careful design is critical to the success of a small trial.
Second, adequate resources are needed to recruit and
enroll patients. Cost-savings approaches to study design can
help somewhat, but this is an especially relevant concern
when significant costs may be associated with a single
intervention or additional personnel are needed for detailed
follow-up that is more in-depth than routine standard of
care. Frequently, traditional sources of funding are granted
on the basis of existing preliminary data. Sponsorship for
the small trials that generate that initial data can be harder
to come by. Industry, departmental, or societal support may
be options in some cases. These avenues should be pursued,
as having sufficient staff and support can be critical for
meeting target enrollment and successfully conducting the
intervention. Individual centers may be volunteering efforts
to conduct these studies, which may not be sustainable or
may substantially limit what can be done. There certainly
is a need for more readily available funding to support
promising efforts to conduct small-scale studies that may
provide intriguing results or provide a basis for larger trials.
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Finally, it is essential to have an appropriate plan for
analysis of the study data. Often, due to power and sample
size concerns, there can be significant challenges getting
these studies published. Clearly describing the purpose of
the study and the design can be helpful when presenting
pilot data. An analysis plan should be decided on a priori,
and again it is critical to have a proper comparison group.
Appropriate statistics should be used and the results should
be reported with a discussion of the limitations. When
conducted, analyzed, and presented appropriately, small
studies can have an impact on the field.
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